GPNMB and neoplasm: For instance, engineered senolytic EVs, conjugated with anti‐GPNMB antibodies and loaded with the combination drug D+Q, have demonstrated efficient and selective eradication of senescent tumour cells, thereby activating anti‐tumour immunity in a murine model.163